Our Pricing

Understanding Wegovy and Semaglutide: Your UK Prescription Guide

Published on: June 03, 2026

If you're wondering is Wegovy semaglutide UK-licensed, the answer is yes — Wegovy is the brand name for injectable semaglutide specifically approved by the MHRA for chronic weight management. At Cured Pharmacy, our UK-registered clinical team can assess your suitability for Wegovy from £79.00, with transparent pricing shown before your free online consultation.

Is Wegovy Semaglutide? Understanding the Difference

Wegovy is the brand name for semaglutide 2.4mg injectable pens manufactured by Novo Nordisk and licensed in the UK specifically for weight management [1]. Semaglutide is the active pharmaceutical ingredient — a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 to regulate appetite and food intake.

The confusion often arises because semaglutide is also marketed under different brand names for different indications. Ozempic contains the same active ingredient but at lower doses (0.25mg to 1mg) and is licensed solely for type 2 diabetes management, not weight loss [2]. Wegovy pens deliver higher therapeutic doses (up to 2.4mg weekly) specifically calibrated for chronic weight management in adults with a BMI of 30 or above, or 27 or above with weight-related comorbidities.

When UK prescribers assess patients for weight loss treatment, they evaluate whether the higher-dose Wegovy formulation is clinically appropriate based on your medical history, current medications, and weight management goals. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription dispensed meets MHRA standards for safety and efficacy.

How Wegovy Semaglutide Works for Weight Loss

Semaglutide in Wegovy activates GLP-1 receptors in the brain's appetite regulation centres, particularly in the hypothalamus and brainstem [3]. This activation slows gastric emptying, increases feelings of fullness after meals, and reduces hunger signals between meals — creating a physiological environment that supports sustained calorie reduction without the intense hunger typical of traditional calorie-restriction diets.

In the landmark STEP 1 clinical trial involving 1,961 adults without diabetes, participants using semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group [1]. Importantly, 86.4% of semaglutide-treated participants achieved at least 5% weight loss, and 69.1% achieved at least 10% weight loss — thresholds associated with meaningful improvements in cardiovascular and metabolic health markers.

The medication works best when combined with a reduced-calorie diet and increased physical activity, as recommended by NICE guidelines [4]. Your UK prescriber will discuss realistic expectations during your consultation, as individual responses vary based on baseline weight, adherence to lifestyle modifications, and metabolic factors.

Expected Timeline for Results

Most patients begin noticing reduced appetite within the first 1-2 weeks of treatment, though measurable weight loss typically becomes evident after 4-8 weeks [1]. Wegovy follows a dose-escalation schedule starting at 0.25mg weekly, gradually increasing every four weeks to minimise gastrointestinal side effects whilst allowing your body to adapt to the medication's effects. The full maintenance dose of 2.4mg weekly is usually reached by week 17, with maximum weight loss effects observed between months 6-12 of continuous treatment.

Wegovy vs Other Semaglutide Products in the UK

Understanding which semaglutide formulation suits your needs requires clarity on the UK-licensed options available. Wegovy (semaglutide 2.4mg) is the only semaglutide product licensed by the MHRA specifically for chronic weight management. Ozempic, whilst containing the same active ingredient, is licensed exclusively for type 2 diabetes and prescribing it off-label for weight loss falls outside its marketing authorisation.

Some UK pharmacies may offer compounded semaglutide preparations, but these lack the rigorous clinical trial data, quality assurance, and regulatory oversight that comes with MHRA-licensed Wegovy pens. At Cured Pharmacy, we dispense only genuine UK-licensed medicines sourced through verified pharmaceutical supply chains, ensuring every pen meets the same manufacturing standards as those used in the STEP clinical trials.

The distinction matters for safety and efficacy. Wegovy pens are pre-filled, single-dose injectors calibrated precisely for weight management dosing schedules, whereas Ozempic pens use different dose increments designed for glycaemic control. Using the wrong formulation or dose can compromise treatment outcomes and increase the risk of adverse effects.

Wegovy Semaglutide Dosing and Administration

Wegovy is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm [5]. The pre-filled pen design makes self-administration straightforward — most patients become comfortable with the injection technique after the first 1-2 doses. Each pen is single-use and disposed of in a sharps container, which your pharmacy can provide.

The standard dose-escalation schedule begins at 0.25mg weekly for four weeks, increasing to 0.5mg, then 1mg, 1.7mg, and finally the maintenance dose of 2.4mg weekly [5]. This gradual titration significantly reduces the incidence and severity of gastrointestinal side effects such as nausea and vomiting, which are most common during dose increases. If you experience persistent side effects, your prescriber may recommend staying at your current dose for an additional four weeks before escalating.

Consistency matters for optimal results. Injecting on the same day each week helps maintain stable semaglutide levels in your system. If you miss a dose and it's been less than five days, take it as soon as you remember. If more than five days have passed, skip that dose and resume your regular schedule — never double up to compensate for a missed injection.

Storage and Handling Requirements

Unopened Wegovy pens must be stored in a refrigerator between 2°C and 8°C until first use. Once in use, pens can be stored at room temperature (below 30°C) or continued in the refrigerator for up to 28 days [5]. Never freeze Wegovy pens, and discard any pen that has been frozen. Keep pens in the original carton to protect from light, and ensure the pen cap is replaced after each injection to maintain sterility.

Common Side Effects and Safety Considerations

The most frequently reported side effects in the STEP trials were gastrointestinal: nausea (44% of participants), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These effects are typically mild to moderate, occur predominantly during dose escalation, and diminish over time as your body adapts to the medication. Eating smaller, more frequent meals and avoiding high-fat foods can help manage these symptoms.

More serious but rare risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not conclusively demonstrated in humans) [5]. Your UK prescriber will screen for contraindications including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 before prescribing Wegovy. You should seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, or signs of pancreatitis.

Semaglutide can interact with other medications, particularly those affecting blood sugar levels. If you're taking insulin or sulphonylureas, dose adjustments may be necessary to prevent hypoglycaemia. During your free online consultation at Cured Pharmacy, our UK prescribers review your complete medication list to identify potential interactions and ensure Wegovy is safe for you.

Getting Your Wegovy Prescription from Cured Pharmacy

Accessing Wegovy through Cured Pharmacy begins with a free online consultation that takes under three minutes to complete. You'll answer questions about your weight history, current health conditions, medications, and weight loss goals. A UK-registered prescriber reviews your assessment within hours, not days, and determines whether Wegovy is clinically appropriate for your circumstances.

If approved, your prescription is sent directly to our dispensary where superintendent pharmacist Tarun Kumar (GPhC 2233073) and our team prepare your order using genuine UK-licensed Wegovy pens. We offer discreet packaging with no external branding, and delivery options include next-day service to anywhere in the UK. Pricing is transparent from the start — you'll see the exact cost (from £79.00) before completing your consultation, with no hidden fees or surprise charges.

Ongoing support is included with every prescription. As you progress through the dose-escalation schedule, you can message our clinical team with questions about side effects, injection technique, or treatment adjustments. We also coordinate repeat prescriptions to ensure you never run out of medication, maintaining treatment continuity that's essential for sustained weight loss results.

Why Choose Cured Pharmacy for Wegovy

As a fully registered UK pharmacy (GPhC 9012511), we operate under the same regulatory standards as high-street pharmacies whilst offering the convenience and competitive pricing of online service. Our lowest price guarantee ensures you're getting the best value for genuine, MHRA-licensed Wegovy without compromising on quality or clinical safety. Every prescription is individually assessed by UK prescribers who understand the nuances of weight management pharmacotherapy and can tailor treatment to your specific needs.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Pieber, T. R., Hartoft-Nielsen, M. L., et al. (2017). Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes. JAMA, 318(15), 1460–1470. https://doi.org/10.1001/jama.2017.14752 [accessed 13 August 2026]
3. Müller, T. D., Finan, B., Bloom, S. R., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to lifestyle modifications.